- Home
- HCM vs HTFL Comparison
HCM vs HTFL Comparison
Compare HCM & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCM | HTFL |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | HCM | HTFL |
|---|---|---|
| Price | $12.64 | $45.23 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $13.75 | ★ $38.20 |
| AVG Volume (30 Days) | 40.3K | ★ 1.5M |
| Earning Date | 03-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,034,000.00 |
| Revenue This Year | $20.60 | $27.66 |
| Revenue Next Year | $15.62 | $23.55 |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | ★ 39.92 |
| 52 Week Low | $9.77 | $20.13 |
| 52 Week High | $17.79 | $43.28 |
Technical Indicators
Market Signals| Indicator | HCM | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 63.58 | 84.87 |
| Support Level | $10.73 | $24.59 |
| Resistance Level | $14.80 | N/A |
| Average True Range (ATR) | 0.27 | 2.10 |
| MACD | 0.08 | 2.05 |
| Stochastic Oscillator | 82.02 | 96.46 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About HTFL Heartflow Inc.
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.